NUVL
Nuvalent, Inc. Class A · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website nuvalent.com
- Employees(FY) 89
- ISIN US6707031075
Performance
+4.98%
1W
+9.47%
1M
-17.78%
3M
+22.14%
6M
-3.68%
YTD
+79.44%
1Y
Profile
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Investment Analysis Report: NUVL
Overview
In this investment analysis report, we will delve into the financial statements of NUVL, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash flow...
Technical Analysis of NUVL 2024-05-10
Overview:
In analyzing the technical indicators for NUVL over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for informed decisio...
Recent News & Updates
- 2024-05-17 16:48
- 2024-05-17 06:31
FDA grants breakthrough therapy status for Nuvalent’s NVL-655(Pharmaceutical Technology)
- 2024-05-16 16:23
- 2024-05-16 16:01
- 2024-05-16 04:01
- 2024-05-09 07:19
Nuvalent Q1 Net Loss Widens(MT Newswires)
- 2024-05-09 06:30
- 2024-05-09 01:56
NUVL Stock Earnings: Nuvalent Misses EPS for Q1 2024(Investorplace)
- 2024-05-08 21:27
Nuvalent Q1 Loss Widens(Rttnews)
- 2024-05-08 18:30
- 2024-05-08 17:22
- 2024-05-08 10:21
- 2024-05-07 22:21
- 2024-05-01 17:05
- 2024-04-08 16:30
- 2024-04-08 04:30
- 2024-04-05 19:00
- 2024-04-05 18:30
- 2024-03-29 19:01
- 2024-03-25 19:01
- 2024-03-22 09:35
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth(Simply Wall St.)
- 2024-03-19 19:01
- 2024-03-05 16:52
- 2024-03-05 03:52
- 2024-02-29 04:32
- 2024-02-27 06:30
- 2024-02-27 06:15
- 2024-02-26 17:30
- 2024-02-26 17:15
- 2024-02-22 04:00
13 Best Short Squeeze Stocks To Buy Now(Insider Monkey)
Page 1 of 5
previousnext